- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05142488
Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine
December 1, 2021 updated by: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Study of Immunogenicity Equivalence After a Homologous Third Dose of Covid-19 (Recombinante) Vaccine, 6 Months After the Second Dose, Comparing Intervals of 8 and 12 Weeks Between the First Two Doses.
The purpose of this study is to evaluate the antibody response, safety and reactogenicity of a third dose Covid-19 (recombinante) vaccine, 6 months after a two-dose vaccine schedule using the same vaccine in all doses.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
After being informed about the study and potential risks, all participants giving written informed consent will be evaluated for eligibility criteria.
At day 0, participants who meet the eligibility requirements will undergo a thorough medical evaluation and a urine pregnancy test (if applicable).
Previous vaccination information will be collected with the participant and checked via digital Covid-19 vaccine certification from the Brazilian public health national immunization program system (SI-PNI) ou from Fundação Oswaldo Cruz (Fiocruz) institutional occupational medicine data.
According to the data collected, participants will be placed in one of two groups: 8 or 12 weeks interval between the first two vaccine doses in the vaccine schedule.
Eligible and consenting participants will have a blood sample collected and receive immediately after a third dose of the Covid-19 (recombinante) vaccine.
Participants will be instructed to fill out an adverse events journal for solicited adverse events for 7 days and non-solicited adverse events for 28 days after the third dose.
The research team will contact the participant remotely at least once during the first two weeks.
The participant will return for a follow-up visit to the research center 28 days after the third dose, to evaluate adverse events, collect a second blood sample and undergo a thorough medical evaluation.
The participant will return to the research center to collect blood samples in three more follow-up visits: 3 months, 6 months and 12 months after the third dose.
Study Type
Interventional
Enrollment (Anticipated)
662
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Robson Leite de Souza Cruz
- Phone Number: 3689 (21) 3882-7000
- Email: robson.cruz@bio.fiocruz.br
Study Locations
-
-
-
Rio de Janeiro, Brazil, 21040-900
- Recruiting
- Unidade de Ensaios Clínicos em Imunobiológicos
-
Contact:
- Maria Vitoria Hadland Seidl, MD
- Phone Number: (21)99711-1070
- Email: maria.seidl@bio.fiocruz.br
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Employee of Fundação Oswaldo Cruz, stationed in Manguinhos campus, in Rio de Janeiro.
- Previous two-dose vaccine schedule with Covid-19 (recombinante) in both doses, with an interval of8 or 12 weeks between doses.
- A 6-month interval (5 to 7 month window) between the second and the third dose of Covid-19 (recombinante) vaccine.
- Availability to participate during the entire study, and ability to follow study protocol strictly.
- Consent to supply personal contact information, such as telephone numbers, address and other information so the research team may contact the participant (For example, in case the participant fails to attend a scheduled visit without previous notice)
- Ability to understand and sign the volunteered and informed consent form, and ability to fill in the adverse events journal at home, according to the evaluation of the principal investigator ou delegated research team members.
- Understanding the impossibility of participating in another clinical trial while participating in this clinical trial.
Exclusion Criteria:
- Receiving another Covid-19 vaccine after inclusion in the study
- Receiving any vaccine 28 days after administration of a third dose of Covid-19 (recombinante) vaccine.
- Refusal to sign the voluntary and informed consent form or refusal to permit collection of blood samples before the third dose of the Covid-19 (recombinante) vaccine.
- Receiving any other vaccine 28 days before the inclusion in the study
- Previous vaccine schedule with other Covid-19 vaccines, in the first and/or second dose.
- Covid-19 disease confirmed by RT-PCR (Real time polymerase chain reaction) up to 28 days before inclusion in the study.
- Covid-19 symptoms up to 10 days before the inclusion in the study.
- Fever (Axillary temperature above 37,8 º C / 100,04 °F) 72 hours before vaccination in the study.
- Contraindications to the Covid-19 (recombinante) vaccine - Fiocruz/AstraZeneca
- Use of immunosuppressive medication, such as systemic corticosteroids or chemotherapy, or immunosuppressive diseases. We will consider as immunosuppressive doses of systemic corticosteroids daily doses of prednisone of 10mg or more, for more than 14 days.
- Incapacitating mental illness
- Any discoveries made by the principal investigator that would enhance the risk of an adverse result following the participation in the study, or that in some other way justifies exclusion from the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 8 week interval
Third dose Covid-19 (recombinante) vaccine 6 months after the second dose of a two dose vaccine schedule with a 8 week interval between the first two doses.
|
Third dose of the Covid-19 (recombinante) vaccine, 6 months after the second dose of a two dose Covid-19 (recombinante) homologous vaccine schedule.
|
Active Comparator: 12 week interval
Third dose Covid-19 (recombinante) vaccine 6 months after the second dose of a two dose vaccine schedule with a 12 week interval between the first two doses.
|
Third dose of the Covid-19 (recombinante) vaccine, 6 months after the second dose of a two dose Covid-19 (recombinante) homologous vaccine schedule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IgG Anti-S response after a third dose of Covid-19 (recombinante) vaccine
Time Frame: 28 days
|
Equivalence of antibody IgG Anti-S response in geometric mean titers, measured immediately before and 28 days after a third dose of Covid-19 (recombinante) vaccine, administered 6 months after the second dose of a two-dose homologous Covid-19 (recombinante) vaccine schedule, between participants with an 8 and 12 week interval between the first two doses.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Immunogenicity after the third dose of Covid-19 (recombinate) vaccine after 3, 6 and 12 months
Time Frame: 15 months
|
Antibody IgG Anti-S collected immediately before, 28 days, 3 months, 6 months and 12 months after the third dose of Covid-19 (recombinante) vaccine.
|
15 months
|
Safety and reactogenicity of a third dose of Covid-19 (recombinate) vaccine
Time Frame: 15 months
|
Safety and reactogenicity after a third dose of Covid-19 (recombinate) vaccine, 7 days for solicited adverse events, 28 days for non-solicited adverse events and 12 months for serious adverse events.
|
15 months
|
Neutralizing antibodies in plaque reduction neutralization test (PRNT) in a smaller sample
Time Frame: 28 days
|
Measure neutralizing antibodies in plaque reduction neutralization test (PRNT) in a smaller sample of participants, immediately before and 28 days after the third dose.
|
28 days
|
IgG Anti-S response after a third dose of Covid-19 (recombinante) vaccine by age groups
Time Frame: 1 month
|
Equivalence of antibody IgG Anti-S response in geometric mean titers, measured immediately before and 28 days after a third dose of Covid-19 (recombinante) vaccine, administered 6 months after the second dose of a two-dose homologous Covid-19 (recombinante) vaccine schedule, between participants with an 8 and 12 week interval between the first two doses.
Compare results between participants with 40 years or less, 40 to 60 years, or more than 60 years.
|
1 month
|
Duration of Immunogenicity after the third dose of Covid-19 (recombinate) vaccine after 3, 6 and 12 months by age groups
Time Frame: 15 months
|
Antibody IgG Anti-S collected immediately before, 28 days, 3 months, 6 months and 12 months after the third dose of Covid-19 (recombinante) vaccine.
Compare results between participants with 40 years or less, 40 to 60 years, or more than 60 years.
|
15 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 9, 2021
Primary Completion (Anticipated)
March 30, 2022
Study Completion (Anticipated)
March 30, 2023
Study Registration Dates
First Submitted
November 30, 2021
First Submitted That Met QC Criteria
December 1, 2021
First Posted (Actual)
December 2, 2021
Study Record Updates
Last Update Posted (Actual)
December 2, 2021
Last Update Submitted That Met QC Criteria
December 1, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASCLIN 009/2021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Covid -19 (recombinante) vaccine
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Active, not recruiting
-
Hospital Moinhos de VentoPfizer; Universidade Federal do Paraná; Inova MedicalCompleted
-
Thomas Jefferson UniversityNemoursActive, not recruiting
-
WestVac Biopharma Co., Ltd.Active, not recruitingCOVID-19 | SARS-CoV-2 InfectionMexico
-
Huntington Memorial HospitalCompletedCovid19 | Vaccine ReactionUnited States
-
University Health Network, TorontoCanadian Institutes of Health Research (CIHR); Samuel Lunenfeld Research Institute... and other collaboratorsActive, not recruitingVaccine Response | COVID-19 Virus InfectionCanada
-
Laboratorios Hipra, S.A.CompletedCovid19 | SARS CoV 2 InfectionSpain
-
ModernaTX, Inc.Active, not recruiting
-
Centre Hospitalier Universitaire de Saint EtienneSanofi Pasteur, a Sanofi Company; Bioster, a.s.Completed
-
Canadian Immunization Research NetworkMassachusetts General Hospital; CHU de Quebec-Universite Laval; McGill University... and other collaboratorsActive, not recruiting